Catalent en las noticias
Socio de fabricación para el desarrollo de fármacos
Tamtam encontró 20 artículos recientes sobre Catalent.
- Catalent launches ten-month gene-to-drug substance programme for complex biologics
- Catalent, Inc. Launches Accelerated Gene-To-Drug Substance Program For Complex Biologics In The U.S
- Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.
- Catalent Launches Accelerated Gene-to-Drug Substance Program in US for Complex Biologics
- ALK-Abelló (CPSE:ALK B) Expands Catalent Deal, Is The 32% Undervaluation Case Convincing?
- ALK expands Catalent partnership: what it means for Catalent stock
- ALK expands strategic tablet supply partnership with Catalent
- ALK expands Catalent partnership – guidance is maintained
- ALK Expands Tablet Supply Partnership With Catalent
- ALK, Catalent Expand Long-Term Contract Manufacturing Collaboration
- ALK expands strategic tablet supply partnership with Catalent
- Catalent stock reports USD 4.7 billion refinancing
- Catalent stock holds near its yearly low as earnings lag
- Catalent stock gains after FDA clears key manufacturing site
- Catalent stock holds steady as investors await fresh earnings and guidance
- Catalent lands $4.1B debt deal to expand biologics and oral drug capacity
- Catalent uses AI on Azure to strengthen quality management system processes
- Catalent Completes $4.1 Billion Debt Refinancing To Cut Annual Interest Expense By $100 Million
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Catalent Completes Successful Debt Refinancing
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Catalent?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares